All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
17Feb20 17:30 RNS Summit Therapeutics Health £68.9m Summit Therapeutics
11Feb20 10:00 GNW Summit Therapeutics Health £68.9m AIM Delisting Reminder
10Feb20 14:15 GNW Summit Therapeutics Health £68.9m Director/PDMR Shareholding
06Feb20 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
04Feb20 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
27Jan20 07:00 GNW Summit Therapeutics Health £68.9m Exercise of Restricted Stock Units
24Jan20 12:00 GNW Summit Therapeutics Health £68.9m Summit Announces Management Update
23Jan20 12:00 GNW Summit Therapeutics Health £68.9m Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
20Jan20 14:15 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
20Jan20 14:15 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
15Jan20 12:15 GNW Summit Therapeutics Health £68.9m Notification of Transactions of Persons Discharging Managerial Responsibilities
07Jan20 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
31Dec19 09:00 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
30Dec19 07:00 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
24Dec19 08:30 GNW Summit Therapeutics Health £68.9m Completion of $50 million Fundraising and Directorate Change
24Dec19 07:01 GNW Summit Therapeutics Health £68.9m Award of Share Options
24Dec19 07:00 GNW Summit Therapeutics Health £68.9m Exercise of Restricted Stock Units
23Dec19 12:00 GNW Summit Therapeutics Health £68.9m Result of General Meeting
19Dec19 07:00 GNW Summit Therapeutics Health £68.9m Timetable Update
17Dec19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
16Dec19 14:15 GNW Summit Therapeutics Health £68.9m Notice of Q3 Results
06Dec19 12:00 GNW Summit Therapeutics Health £68.9m Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
06Nov19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
04Nov19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Recognises C. difficile Awareness Month
16Oct19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the 2019 BIO Investor Forum
11Oct19 12:01 GNW Summit Therapeutics Health £68.9m Directorate change
11Oct19 12:00 GNW Summit Therapeutics Health £68.9m Half-year report
10Oct19 14:30 GNW Summit Therapeutics Health £68.9m Notice of Results
07Oct19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
03Oct19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
25Sep19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Host R&D Day 7 October 2019
24Sep19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
18Sep19 07:00 GNW Summit Therapeutics Health £68.9m Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
05Sep19 12:00 GNW Summit Therapeutics Health £68.9m Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
04Sep19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Participate in Upcoming Investor Conferences
01Aug19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
17Jul19 12:00 GNW Summit Therapeutics Health £68.9m Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
09Jul19 12:00 GNW Summit Therapeutics Health £68.9m Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
20Jun19 12:00 GNW Summit Therapeutics Health £68.9m Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19Jun19 12:00 GNW Summit Therapeutics Health £68.9m Result of AGM
18Jun19 12:00 GNW Summit Therapeutics Health £68.9m Increased BARDA Award and Option Exercise
12Jun19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
05Jun19 14:00 GNW Summit Therapeutics Health £68.9m Notice of First Quarter Results
14May19 17:30 GNW Summit Therapeutics Health £68.9m UK Annual Report and Notice of AGM
24Apr19 16:20 GNW Summit Therapeutics Health £68.9m Exercise of Restricted Stock Units
15Apr19 07:00 GNW Summit Therapeutics Health £68.9m Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
03Apr19 12:00 GNW Summit Therapeutics Health £68.9m Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
02Apr19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29Mar19 17:45 GNW Summit Therapeutics Health £68.9m Award of Share Options
29Mar19 11:15 GNW Summit Therapeutics Health £68.9m Filing of Annual Report on Form 20-F
27Mar19 11:00 GNW Summit Therapeutics Health £68.9m Final Results
25Mar19 11:00 GNW Summit Therapeutics Health £68.9m Notice of Results
18Mar19 11:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at Upcoming Conferences
14Mar19 11:00 GNW Summit Therapeutics Health £68.9m Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25Feb19 12:00 GNW Summit Therapeutics Health £68.9m Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13Feb19 12:00 GNW Summit Therapeutics Health £68.9m Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
08Feb19 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the BIO CEO & Investor Conference
15Jan19 17:45 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
14Jan19 12:00 GNW Summit Therapeutics Health £68.9m Award of Restricted Stock Units
10Jan19 16:15 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
10Jan19 11:30 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
10Jan19 07:00 GNW Summit Therapeutics Health £68.9m Completion of $25 million Subscription
09Jan19 16:45 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
08Jan19 07:00 GNW Summit Therapeutics Health £68.9m Update on Admission
04Jan19 12:30 GNW Summit Therapeutics Health £68.9m Result of General Meeting
02Jan19 09:40 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
18Dec18 12:15 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
17Dec18 07:05 GNW Summit Therapeutics Health £68.9m Proposed Subscription to Raise $25m and Notice of General Meeting
17Dec18 07:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Announces Departure of Chief Financial Officer
11Dec18 12:00 GNW Summit Therapeutics Health £68.9m 3rd Quarter Results
06Dec18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30Nov18 13:30 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
12Nov18 12:00 GNW Summit Therapeutics Health £68.9m Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12Nov18 07:00 GNW Summit Therapeutics Health £68.9m Appointment of Joint Broker
07Nov18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
01Nov18 16:34 GNW Summit Therapeutics Health £68.9m Holding(s) in Company
01Nov18 11:00 GNW Summit Therapeutics Health £68.9m Summit Recognises C. difficile Awareness Month
24Oct18 16:15 GNW Summit Therapeutics Health £68.9m Director/PDMR Shareholding
22Oct18 07:00 GNW Summit Therapeutics Health £68.9m Award of Share Options
29Aug18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
16Aug18 12:00 GNW Summit Therapeutics Health £68.9m Summit Awarded Additional $12 Million by BARDA for Ridinilazole
06Aug18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
03Aug18 07:00 GNW Summit Therapeutics Health £68.9m Phase 2 Clinical Data Published Showing Summit's Ridinilazole Preserved Gut Microbiome of Patients with CDI
19Jul18 07:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Director/PDMR Shareholding
17Jul18 07:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Director/PDMR Shareholding
16Jul18 07:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Director/PDMR Shareholding
02Jul18 17:48 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Holding(s) in Company
02Jul18 17:47 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Holding(s) in Company
27Jun18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint
15Jun18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
11Jun18 07:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
07Jun18 12:45 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Result of AGM
05Jun18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : 1st Quarter Results
01Jun18 12:00 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Notice of 1st Quarter Results
03May18 10:15 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Notice of AGM
02May18 15:30 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Holding(s) in Company
01May18 11:30 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Total voting rights
23Apr18 17:05 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Director/PDMR Shareholding
23Apr18 12:00 GNW Summit Therapeutics Health £68.9m Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
23Apr18 11:45 GNW Summit Therapeutics Health £68.9m Summit Therapeutics plc : Grant of Share Options and RSUs
Date / Time Source Company % Chg
17Feb20 17:30 RNS Summit Therapeutics 0.00%
Summit Therapeutics
11Feb20 10:00 GNW Summit Therapeutics 0.00%
AIM Delisting Reminder
10Feb20 14:15 GNW Summit Therapeutics 0.00%
Director/PDMR Shareholding
06Feb20 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
04Feb20 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
27Jan20 07:00 GNW Summit Therapeutics 0.00%
Exercise of Restricted Stock Units
24Jan20 12:00 GNW Summit Therapeutics 0.00%
Summit Announces Management Update
23Jan20 12:00 GNW Summit Therapeutics 0.00%
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
20Jan20 14:15 GNW Summit Therapeutics 0.00%
Holding(s) in Company
20Jan20 14:15 GNW Summit Therapeutics 0.00%
Holding(s) in Company
15Jan20 12:15 GNW Summit Therapeutics 0.00%
Notification of Transactions of Persons Discharging Managerial Responsibilities
07Jan20 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
31Dec19 09:00 GNW Summit Therapeutics 0.00%
Holding(s) in Company
30Dec19 07:00 GNW Summit Therapeutics 0.00%
Holding(s) in Company
24Dec19 08:30 GNW Summit Therapeutics 0.00%
Completion of $50 million Fundraising and Directorate Change
24Dec19 07:01 GNW Summit Therapeutics 0.00%
Award of Share Options
24Dec19 07:00 GNW Summit Therapeutics 0.00%
Exercise of Restricted Stock Units
23Dec19 12:00 GNW Summit Therapeutics 0.00%
Result of General Meeting
19Dec19 07:00 GNW Summit Therapeutics 0.00%
Timetable Update
17Dec19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
16Dec19 14:15 GNW Summit Therapeutics 0.00%
Notice of Q3 Results
06Dec19 12:00 GNW Summit Therapeutics 0.00%
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
06Nov19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
04Nov19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Recognises C. difficile Awareness Month
16Oct19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the 2019 BIO Investor Forum
11Oct19 12:01 GNW Summit Therapeutics 0.00%
Directorate change
11Oct19 12:00 GNW Summit Therapeutics 0.00%
Half-year report
10Oct19 14:30 GNW Summit Therapeutics 0.00%
Notice of Results
07Oct19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
03Oct19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
25Sep19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Host R&D Day 7 October 2019
24Sep19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
18Sep19 07:00 GNW Summit Therapeutics 0.00%
Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
05Sep19 12:00 GNW Summit Therapeutics 0.00%
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
04Sep19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Participate in Upcoming Investor Conferences
01Aug19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
17Jul19 12:00 GNW Summit Therapeutics 0.00%
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
09Jul19 12:00 GNW Summit Therapeutics 0.00%
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
20Jun19 12:00 GNW Summit Therapeutics 0.00%
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19Jun19 12:00 GNW Summit Therapeutics 0.00%
Result of AGM
18Jun19 12:00 GNW Summit Therapeutics 0.00%
Increased BARDA Award and Option Exercise
12Jun19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
05Jun19 14:00 GNW Summit Therapeutics 0.00%
Notice of First Quarter Results
14May19 17:30 GNW Summit Therapeutics 0.00%
UK Annual Report and Notice of AGM
24Apr19 16:20 GNW Summit Therapeutics 0.00%
Exercise of Restricted Stock Units
15Apr19 07:00 GNW Summit Therapeutics 0.00%
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
03Apr19 12:00 GNW Summit Therapeutics 0.00%
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
02Apr19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29Mar19 17:45 GNW Summit Therapeutics 0.00%
Award of Share Options
29Mar19 11:15 GNW Summit Therapeutics 0.00%
Filing of Annual Report on Form 20-F
27Mar19 11:00 GNW Summit Therapeutics 0.00%
Final Results
25Mar19 11:00 GNW Summit Therapeutics 0.00%
Notice of Results
18Mar19 11:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at Upcoming Conferences
14Mar19 11:00 GNW Summit Therapeutics 0.00%
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25Feb19 12:00 GNW Summit Therapeutics 0.00%
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13Feb19 12:00 GNW Summit Therapeutics 0.00%
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
08Feb19 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the BIO CEO & Investor Conference
15Jan19 17:45 GNW Summit Therapeutics 0.00%
Holding(s) in Company
14Jan19 12:00 GNW Summit Therapeutics 0.00%
Award of Restricted Stock Units
10Jan19 16:15 GNW Summit Therapeutics 0.00%
Holding(s) in Company
10Jan19 11:30 GNW Summit Therapeutics 0.00%
Holding(s) in Company
10Jan19 07:00 GNW Summit Therapeutics 0.00%
Completion of $25 million Subscription
09Jan19 16:45 GNW Summit Therapeutics 0.00%
Holding(s) in Company
08Jan19 07:00 GNW Summit Therapeutics 0.00%
Update on Admission
04Jan19 12:30 GNW Summit Therapeutics 0.00%
Result of General Meeting
02Jan19 09:40 GNW Summit Therapeutics 0.00%
Holding(s) in Company
18Dec18 12:15 GNW Summit Therapeutics 0.00%
Holding(s) in Company
17Dec18 07:05 GNW Summit Therapeutics 0.00%
Proposed Subscription to Raise $25m and Notice of General Meeting
17Dec18 07:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Announces Departure of Chief Financial Officer
11Dec18 12:00 GNW Summit Therapeutics 0.00%
3rd Quarter Results
06Dec18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30Nov18 13:30 GNW Summit Therapeutics 0.00%
Holding(s) in Company
12Nov18 12:00 GNW Summit Therapeutics 0.00%
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12Nov18 07:00 GNW Summit Therapeutics 0.00%
Appointment of Joint Broker
07Nov18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
01Nov18 16:34 GNW Summit Therapeutics 0.00%
Holding(s) in Company
01Nov18 11:00 GNW Summit Therapeutics 0.00%
Summit Recognises C. difficile Awareness Month
24Oct18 16:15 GNW Summit Therapeutics 0.00%
Director/PDMR Shareholding
22Oct18 07:00 GNW Summit Therapeutics 0.00%
Award of Share Options
29Aug18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
16Aug18 12:00 GNW Summit Therapeutics 0.00%
Summit Awarded Additional $12 Million by BARDA for Ridinilazole
06Aug18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
03Aug18 07:00 GNW Summit Therapeutics 0.00%
Phase 2 Clinical Data Published Showing Summit's Ridinilazole Preserved Gut Microbiome of Patients with CDI
19Jul18 07:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
17Jul18 07:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
16Jul18 07:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
02Jul18 17:48 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Holding(s) in Company
02Jul18 17:47 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Holding(s) in Company
27Jun18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint
15Jun18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
11Jun18 07:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
07Jun18 12:45 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Result of AGM
05Jun18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : 1st Quarter Results
01Jun18 12:00 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Notice of 1st Quarter Results
03May18 10:15 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Notice of AGM
02May18 15:30 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Holding(s) in Company
01May18 11:30 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Total voting rights
23Apr18 17:05 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
23Apr18 12:00 GNW Summit Therapeutics 0.00%
Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
23Apr18 11:45 GNW Summit Therapeutics 0.00%
Summit Therapeutics plc : Grant of Share Options and RSUs
Date / Time Company % Chg
17Feb20 17:30 Summit Therapeutics 0.00%
Summit Therapeutics
11Feb20 10:00 Summit Therapeutics 0.00%
AIM Delisting Reminder
10Feb20 14:15 Summit Therapeutics 0.00%
Director/PDMR Shareholding
06Feb20 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
04Feb20 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
27Jan20 07:00 Summit Therapeutics 0.00%
Exercise of Restricted Stock Units
24Jan20 12:00 Summit Therapeutics 0.00%
Summit Announces Management Update
23Jan20 12:00 Summit Therapeutics 0.00%
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
20Jan20 14:15 Summit Therapeutics 0.00%
Holding(s) in Company
20Jan20 14:15 Summit Therapeutics 0.00%
Holding(s) in Company
15Jan20 12:15 Summit Therapeutics 0.00%
Notification of Transactions of Persons Discharging Managerial Responsibilities
07Jan20 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
31Dec19 09:00 Summit Therapeutics 0.00%
Holding(s) in Company
30Dec19 07:00 Summit Therapeutics 0.00%
Holding(s) in Company
24Dec19 08:30 Summit Therapeutics 0.00%
Completion of $50 million Fundraising and Directorate Change
24Dec19 07:01 Summit Therapeutics 0.00%
Award of Share Options
24Dec19 07:00 Summit Therapeutics 0.00%
Exercise of Restricted Stock Units
23Dec19 12:00 Summit Therapeutics 0.00%
Result of General Meeting
19Dec19 07:00 Summit Therapeutics 0.00%
Timetable Update
17Dec19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
16Dec19 14:15 Summit Therapeutics 0.00%
Notice of Q3 Results
06Dec19 12:00 Summit Therapeutics 0.00%
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
06Nov19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
04Nov19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Recognises C. difficile Awareness Month
16Oct19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the 2019 BIO Investor Forum
11Oct19 12:01 Summit Therapeutics 0.00%
Directorate change
11Oct19 12:00 Summit Therapeutics 0.00%
Half-year report
10Oct19 14:30 Summit Therapeutics 0.00%
Notice of Results
07Oct19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
03Oct19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
25Sep19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Host R&D Day 7 October 2019
24Sep19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
18Sep19 07:00 Summit Therapeutics 0.00%
Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
05Sep19 12:00 Summit Therapeutics 0.00%
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
04Sep19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Participate in Upcoming Investor Conferences
01Aug19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
17Jul19 12:00 Summit Therapeutics 0.00%
Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
09Jul19 12:00 Summit Therapeutics 0.00%
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
20Jun19 12:00 Summit Therapeutics 0.00%
Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19Jun19 12:00 Summit Therapeutics 0.00%
Result of AGM
18Jun19 12:00 Summit Therapeutics 0.00%
Increased BARDA Award and Option Exercise
12Jun19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
05Jun19 14:00 Summit Therapeutics 0.00%
Notice of First Quarter Results
14May19 17:30 Summit Therapeutics 0.00%
UK Annual Report and Notice of AGM
24Apr19 16:20 Summit Therapeutics 0.00%
Exercise of Restricted Stock Units
15Apr19 07:00 Summit Therapeutics 0.00%
Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
03Apr19 12:00 Summit Therapeutics 0.00%
Summit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
02Apr19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29Mar19 17:45 Summit Therapeutics 0.00%
Award of Share Options
29Mar19 11:15 Summit Therapeutics 0.00%
Filing of Annual Report on Form 20-F
27Mar19 11:00 Summit Therapeutics 0.00%
Final Results
25Mar19 11:00 Summit Therapeutics 0.00%
Notice of Results
18Mar19 11:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at Upcoming Conferences
14Mar19 11:00 Summit Therapeutics 0.00%
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25Feb19 12:00 Summit Therapeutics 0.00%
Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13Feb19 12:00 Summit Therapeutics 0.00%
Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
08Feb19 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the BIO CEO & Investor Conference
15Jan19 17:45 Summit Therapeutics 0.00%
Holding(s) in Company
14Jan19 12:00 Summit Therapeutics 0.00%
Award of Restricted Stock Units
10Jan19 16:15 Summit Therapeutics 0.00%
Holding(s) in Company
10Jan19 11:30 Summit Therapeutics 0.00%
Holding(s) in Company
10Jan19 07:00 Summit Therapeutics 0.00%
Completion of $25 million Subscription
09Jan19 16:45 Summit Therapeutics 0.00%
Holding(s) in Company
08Jan19 07:00 Summit Therapeutics 0.00%
Update on Admission
04Jan19 12:30 Summit Therapeutics 0.00%
Result of General Meeting
02Jan19 09:40 Summit Therapeutics 0.00%
Holding(s) in Company
18Dec18 12:15 Summit Therapeutics 0.00%
Holding(s) in Company
17Dec18 07:05 Summit Therapeutics 0.00%
Proposed Subscription to Raise $25m and Notice of General Meeting
17Dec18 07:00 Summit Therapeutics 0.00%
Summit Therapeutics Announces Departure of Chief Financial Officer
11Dec18 12:00 Summit Therapeutics 0.00%
3rd Quarter Results
06Dec18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30Nov18 13:30 Summit Therapeutics 0.00%
Holding(s) in Company
12Nov18 12:00 Summit Therapeutics 0.00%
Summit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12Nov18 07:00 Summit Therapeutics 0.00%
Appointment of Joint Broker
07Nov18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
01Nov18 16:34 Summit Therapeutics 0.00%
Holding(s) in Company
01Nov18 11:00 Summit Therapeutics 0.00%
Summit Recognises C. difficile Awareness Month
24Oct18 16:15 Summit Therapeutics 0.00%
Director/PDMR Shareholding
22Oct18 07:00 Summit Therapeutics 0.00%
Award of Share Options
29Aug18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
16Aug18 12:00 Summit Therapeutics 0.00%
Summit Awarded Additional $12 Million by BARDA for Ridinilazole
06Aug18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
03Aug18 07:00 Summit Therapeutics 0.00%
Phase 2 Clinical Data Published Showing Summit's Ridinilazole Preserved Gut Microbiome of Patients with CDI
19Jul18 07:00 Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
17Jul18 07:00 Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
16Jul18 07:00 Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
02Jul18 17:48 Summit Therapeutics 0.00%
Summit Therapeutics plc : Holding(s) in Company
02Jul18 17:47 Summit Therapeutics 0.00%
Summit Therapeutics plc : Holding(s) in Company
27Jun18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint
15Jun18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
11Jun18 07:00 Summit Therapeutics 0.00%
Summit Therapeutics Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
07Jun18 12:45 Summit Therapeutics 0.00%
Summit Therapeutics plc : Result of AGM
05Jun18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics plc : 1st Quarter Results
01Jun18 12:00 Summit Therapeutics 0.00%
Summit Therapeutics plc : Notice of 1st Quarter Results
03May18 10:15 Summit Therapeutics 0.00%
Summit Therapeutics plc : Notice of AGM
02May18 15:30 Summit Therapeutics 0.00%
Summit Therapeutics plc : Holding(s) in Company
01May18 11:30 Summit Therapeutics 0.00%
Summit Therapeutics plc : Total voting rights
23Apr18 17:05 Summit Therapeutics 0.00%
Summit Therapeutics plc : Director/PDMR Shareholding
23Apr18 12:00 Summit Therapeutics 0.00%
Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
23Apr18 11:45 Summit Therapeutics 0.00%
Summit Therapeutics plc : Grant of Share Options and RSUs